Baidu
map

全新优先审评名单出炉,再添28个药品

2017-09-04 佚名 医谷

今日(9月4日),国家食品药品监督管理总局药品审评中心(简称“CDE”)发布《拟纳入优先审评程序药品注册申请的公示(第二十二批)》,将拟优先审评的药品注册申请及其申请人予以公示,根据公示名单,此次入选的28个药品,13个药品为仿制药上市,3个药品为新药临床,其余12个为新药上市,具体名单如下:

今日(9月4日),国家食品药品监督管理总局药品审评中心(简称“CDE”)发布《拟纳入优先审评程序药品注册申请的公示(第二十二批)》,将拟优先审评的药品注册申请及其申请人予以公示,根据公示名单,此次入选的28个药品,13个药品为仿制药上市,3个药品为新药临床,其余12个为新药上市,具体名单如下:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634752, encodeId=4e921634e5269, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Wed Jun 06 12:06:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240587, encodeId=651d24058ec8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Sep 05 06:03:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240552, encodeId=6b0e240552d0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/07/5fd7f6b597acf767e8c3c43ef0485c3f.jpg, createdBy=a1252104908, createdName=金戈铁马, createdTime=Tue Sep 05 01:10:20 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240530, encodeId=745a240530c0, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Tue Sep 05 00:01:56 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634752, encodeId=4e921634e5269, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Wed Jun 06 12:06:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240587, encodeId=651d24058ec8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Sep 05 06:03:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240552, encodeId=6b0e240552d0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/07/5fd7f6b597acf767e8c3c43ef0485c3f.jpg, createdBy=a1252104908, createdName=金戈铁马, createdTime=Tue Sep 05 01:10:20 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240530, encodeId=745a240530c0, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Tue Sep 05 00:01:56 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 130****4638

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1634752, encodeId=4e921634e5269, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Wed Jun 06 12:06:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240587, encodeId=651d24058ec8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Sep 05 06:03:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240552, encodeId=6b0e240552d0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/07/5fd7f6b597acf767e8c3c43ef0485c3f.jpg, createdBy=a1252104908, createdName=金戈铁马, createdTime=Tue Sep 05 01:10:20 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240530, encodeId=745a240530c0, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Tue Sep 05 00:01:56 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 金戈铁马

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1634752, encodeId=4e921634e5269, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Wed Jun 06 12:06:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240587, encodeId=651d24058ec8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Sep 05 06:03:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240552, encodeId=6b0e240552d0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/07/5fd7f6b597acf767e8c3c43ef0485c3f.jpg, createdBy=a1252104908, createdName=金戈铁马, createdTime=Tue Sep 05 01:10:20 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240530, encodeId=745a240530c0, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Tue Sep 05 00:01:56 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 中医痴

    不错的.学习了.谢谢分享!

    0

相关资讯

河南:公立医院全部取消药品加成 中药饮品除外

8月26日下午,河南省卫生计生委、发展改革委、人力资源和社会保障厅、财政厅以及郑州市卫生计生委等有关部门联合召开省会公立医院综合改革动员会,自2017年8月31日零时起,省会所有公立医院全部取消药品加成(中药饮片除外),同步实施医疗服务价格调整和医保报销等配套改革。河南省人力资源和社会保障厅副厅长、省社会保障局局长郑子健,省卫生计生委副主任、党组副书记阚全程等领导出席会议并讲话,省卫生计生委副主任

11月1日起海南公立医疗机构全面实施药品购销“两票制”

近日,海南省政府办公厅印发了《海南省深化医药卫生体制改革2017年重点工作任务》的通知,着力推进分级诊疗、现代医院管理、全民医保、药品供应保障、综合监管5项制度建设,并划分各相关职能部门的职责和任务。其中,9月底前远程医疗要覆盖五指山、临高、保亭、琼中和白沙5个国定贫困县县医院。

定了!三明价格正式被福建全省采纳

这次终于定了!三明价格正式被福建全省采纳!!8月18日,福建福州官网正式下发《福州市医疗保障管理局关于采购三明联合限价挂网药品的通知》,《通知》主要面向福州市医疗保障基金管理中心,各医保定点医疗机构。内容主要为:根据《福建省医疗保障管理委员会办公室关于开展以医保支付结算价为基础的药品联合限价阳光采购工作的通知》(闽医保办〔2017〕16号)和《福建省医疗保障管理委员会办公室关于采购三明联合限价挂网

四川明确“两票制”执行要求

今年4月,四川省发布“两票制”方案,规定过渡期为5个月。近日,该省再次发布《关于规范四川省公立医疗机构药品采购“两票制”执行工作的通知》,明确了“两票制”药品购销过程中的票据处理流程,包括“一票制”情形、“两票制”情形、“三票制”情形等,同时明确,9月7日该省将正式执行“两票制”。

“药品招标这个‘怪兽’何时寿终正寝?”

前些日子,与医疗界几位朋友小聚,谈及药品省级集中招标采购,一位担任某医院院长的朋友脱口而出:“这个‘怪兽’何时寿终正寝?”一句话引来大家的七嘴八舌。事后想来,这句话似乎令有些人感到刺耳,但如果仔细想想这一政策的前世今生并理性地进行分析,此话也未尝不是苦口良药。一、药品省级集中招标采购是改革道路上的前进还是倒退?关于这个问题,可以从以下三个层面来观察。第一,此举与整个国家改革的方向与路径是否一致

重磅!推进药品上市许可持有人制度试点工作再出新政策,有哪些要求

自2016年6月正式启动上市许可持有人试点工作以来,已有一年多的时间,日前,CFDA就此再向京、津、冀、沪等10个药品上市许可持有人制度试点地区发布《关于推进药品上市许可持有人制度试点工作有关事项的通知》(以下简称《通知》),对持有人的权利义务和法律责任、委托生产中的质量管理体系和生产销售全链条的责任体系、跨区域药品监管机构监管衔接、职责划分以及责任落地等问题进行了规定。《通知》强调,持有

Baidu
map
Baidu
map
Baidu
map